Carprodyl F 50 mg, tablets for dogs

Pajjiż: Irlanda

Lingwa: Ingliż

Sors: HPRA (Health Products Regulatory Authority)

Ingredjent attiv:

Carprofen

Disponibbli minn:

Ceva Santé Animale

Kodiċi ATC:

QM01AE91

INN (Isem Internazzjonali):

Carprofen

Dożaġġ:

50 mg/tablet

Għamla farmaċewtika:

Tablet

Tip ta 'preskrizzjoni:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupp terapewtiku:

Dogs

Żona terapewtika:

carprofen

Indikazzjonijiet terapewtiċi:

N.S.A.I.D.

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2008-07-25

Karatteristiċi tal-prodott

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprodyl F 50 mg, tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One tablet contains:
Active ingredient:
Carprofen
50 mg
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablet.
Circular, beige, scored tablets
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of inflammation and pain caused by musculo-skeletal
disorders and degenerative joint disease.
As a follow up to parenteral analgesia in the management of
post-operative pain
4.3 CONTRAINDICATIONS
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in case of known hypersensitivity to active substance or to
any of the excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a possibility of gastro-intestinal
ulceration or bleeding, or where there is evidence of a blood
dyscrasia.
Do not use in pups less than 4 months of age.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to Sections 4.3 and 4.5.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_1_
_/_
_0_
_6_
_/_
_2_
_0_
_1_
_3_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_3_
_1_
_0_
_5_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in aged dogs may involve additional risk. If such a use cannot be
avoided, dogs may require careful clinical
management.
Avoid use in any dehydrated, hypovolaemic or hy